# Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)

> **NCT01822951** · PHASE4 · WITHDRAWN · sponsor: **Ever Neuro Pharma GmbH**

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Cerebrolysin
- **DRUG:** Donepezil

## Key facts

- **NCT ID:** NCT01822951
- **Lead sponsor:** Ever Neuro Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2016-09
- **Final completion:** 2016-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822951, "Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01822951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*